Allergenic Properties of Naturally Occurring Cannabinoids

Watson, E.S.; Murphy, James C.; Turner, Carlton E.

doi:10.1002/jps.2600720831

Cited by 18 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 This finding is in concordance with previous studies reporting contact urticaria and extreme sensitization upon exposure to cannabis flowers and THC and CBN in animal models, respectively. 9,10 Data on the prevalence and types of adverse effects of topical cannabis are lacking. A recent case of fatal Stevens-Johnsons Syndrome was reported upon the use of CBD spray sublingually, 26 reminding users and prescribers that serious adverse events are possible with products often thought of and marketed as natural.…”

Section: Discussionmentioning

confidence: 99%

A Survey of Topical Cannabis Use in Canada

2021

View full text Add to dashboard Cite

Background Since its legalization in Canada, cannabis use has expanded to include commercially available topical formations. Several scientifically unsupported claims regarding the therapeutic efficacy of topical cannabis are also being made. Developing an understanding of the consumer uses of topical cannabis is important for clinicians to provide appropriate counseling and inform potential areas of therapeutic development. We are examining the prevalence, purpose of use, and sources of information regarding topical cannabis in the Canadian population, with a focus on dermatologic uses. Method A cross-sectional, anonymous electronic, voluntary survey was developed to assess the use of topical cannabis amongst adults in Canada. Results Cannabis was used topically at least once by 24.3% of respondents who started the survey. The commonest form of topical cannabis were creams (26.2%). The most common dermatologic conditions being treated with topical cannabis included atopic dermatitis (25%), acne (19%), and anti-aging (16%); for non-dermatologic conditions, common uses were for joint stiffness or tendonitis (30%) and headaches and migraines (27%). Topical cannabis was reported to be most effective for joint stiffness and tendonitis, general muscular soreness, headaches, eczema, pruritus, acne, and psoriasis. Most respondents obtained and received information about topical cannabis from dispensaries. Conclusion Canadians use topical cannabis for a broad range of systemic and dermatologic purposes, most of which have limited evidence. Future clinical studies are required to elucidate the therapeutic efficacy and safety of topical cannabis. Dermatologists should screen their patients for topical cannabis use and be aware of the limited evidence of therapeutic potential.

show abstract

Section: Discussionmentioning

confidence: 99%

A Survey of Topical Cannabis Use in Canada

2021

View full text Add to dashboard Cite

show abstract

“…There is some evidence as well for delayed type hypersensitivity reaction demonstrated by positive patch testing 34 in a forensic worker, and in early in vitro experiments. 74 Eventually,the development of objective diagnostic measures will be helpful in separating true IgE-mediated cannabis allergies from non-immunologic irritant reactions to the plant and the industry.…”

Section: Discussionmentioning

confidence: 99%

Occupational Allergies to Cannabis

Decuyper

Green

Sussman

et al. 2020

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“…THC, the psychoactive constituent, is present in higher concentrations in marijuana (2). In a guinea‐pig maximization test, Watson et al (3) determined the potential of 7 cannabinoids to produce allergic contact dermatitis. Delta 9‐THC and cannabinol were found to be extreme sensitizers.…”

Section: Discussionmentioning

confidence: 99%